Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
7%
Ph phase_3
11
79%
Ph phase_2
1
7%

Phase Distribution

0

Early Stage

1

Mid Stage

12

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
11(84.6%)
Phase 4Post-market surveillance
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(14)

Detailed Status

Completed14

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (7.7%)
Phase 311 (84.6%)
Phase 41 (7.7%)

Trials by Status

completed14100%

Recent Activity

0 active trials
Showing 5 of 14
completed

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

NCT00297362
completedphase_3

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

NCT00216593
completedphase_3

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

NCT00236431
completedphase_2

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

NCT00416169
completedphase_3

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

NCT00236574
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00297362

A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

Completed
NCT00216593Phase 3

Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study

Completed
NCT00236431Phase 3

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed
NCT00416169Phase 2

A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia

Completed
NCT00236574Phase 3

A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment

Completed
NCT00253214Phase 3

Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release Formulation

Completed
NCT00253227Phase 3

A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
NCT00253188Phase 3

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
NCT00240695Phase 3

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

Completed
NCT00261573Phase 3

A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Completed
NCT00253201Phase 3

A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Completed
NCT00216515Phase 4

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Completed
NCT00216502Phase 3

A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's Disease

Completed
NCT00338117Phase 3

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14